NCT05021211

Brief Summary

By doing this study, researchers hope to learn to see if there is relationship between whole egg consumption and brain choline status. Additionally, researchers also plan to see if there is a relationship between brain choline status and cognition.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

August 19, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 25, 2021

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2024

Completed
Last Updated

August 14, 2024

Status Verified

August 1, 2024

Enrollment Period

2.8 years

First QC Date

August 19, 2021

Last Update Submit

August 13, 2024

Conditions

Keywords

CholineEgg ConsumptionAlzheimer DiseaseCognitive ImpairmentDementia

Outcome Measures

Primary Outcomes (2)

  • Association Between Whole Egg Intake and Cerebral Choline

    The investigators will recruit a variety of whole egg consumers. Egg consumption will be validated with a 7-day food record 1 week before the MRI. Cerebral choline levels are measured by magnetic resonance spectroscopy (MRS)

    Baseline

  • Association Between Cerebral Choline and Cognition

    The investigators will test the association between cerebral choline as measured by MRS and cognition. Cognition will be measured by the NIH ToolBox cognitive battery.

    Baseline

Study Arms (3)

Low Egg Consumers

Participants who consume fewer than 1 whole egg per week

Moderate Egg Consumers

Participants who consume 5-9 whole eggs per week

High Egg Consumers

Participants who consumes great than or equal to 14 whole eggs per week

Eligibility Criteria

Age60 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants will be recruited from the greater Kansas City. Recruitment for this research opportunity by email, community flyers, and through the social media platform, Nextdoor. Researchers will also use recruitment databases including the Recruitment and Eligibility Database hosted by the KU Alzheimer's Disease Center (P30 AG035982) and the Pioneers Participant Registry hosted by KU Medical Center and the University of Kansas Hospital. Both of these registries consist of highly characterized, community-dwelling individuals that have given prior consent to be directly contacted for research opportunities.

You may qualify if:

  • Aged between 60 - 85 years of age
  • Good general health with no concomitant diseases
  • Cognitively normal as defined as Mini-mental state examination (MMSE) score ≥ 25
  • BMI range: 20 - 40 kg/m2

You may not qualify if:

  • Presence of central neurological disease (e.g., brain tumor, stroke, epilepsy, motor neuron disease, multiple sclerosis, Alzheimer's, Parkinson's)
  • Prior major head trauma with loss of consciousness
  • Presence of active unstable and life-threatening illness (e.g., cancer)
  • Presence of major psychiatric disorder within the past 3 years including depression, anxiety, and alcohol (over 3 drinks per day or total of 18 per week) or drug abuse (DSM-IV criteria; Geriatric Depression Score \> 6)
  • Presence of diabetes mellitus or use of anti-diabetic agents
  • Use of psychoactive and investigational medications
  • Use of hormone replacement therapy
  • Tobacco smokers
  • Subjects with MRI contraindications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location

MeSH Terms

Conditions

Alzheimer DiseaseCognitive DysfunctionDementia

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersCognition Disorders

Study Officials

  • Debra K. Sullivan, PhD, RD

    University of Kansas Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 19, 2021

First Posted

August 25, 2021

Study Start

June 1, 2021

Primary Completion

April 1, 2024

Study Completion

May 1, 2024

Last Updated

August 14, 2024

Record last verified: 2024-08

Locations